Sent from Windows Mail

From: Hogan, Karen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=EB7DC31713D443F0A322F0163D8D7C73-HOGAN, KAREN] Sent: 5/19/2015 12:49:42 PM To: Jinot, Jennifer [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d0edf66a00054afe84f4ab5c5119562f-Jinot, Jennifer] Subject: FW: Next set of RDX comments... Attachments: RDX_Public Comment draft Toxicological Reviewt_MASTER_5-8-15_HERO_sjjcomments_pages 2-8 to 2-17 and some cancer.docx Sorry, didn't realize when I forwarded that that it was incomplete. It may still be... ----Original Message----From: Rieth, Susan Sent: Monday, May 18, 2015 9:59 AM To: Blessinger, Todd; Hogan, Karen; Persad, Amanda; Fite, Katherine Cc: D'Amico, Louis; Subramaniam, Ravi; Brinkerhoff, Chris Subject: FW: Next set of RDX comments... Hi all. FYI, the latest installment from Samantha. I've saved this to the share drive as the latest master and will start to revise in response to Samantha's comments today. Sue P.S. Samantha did a great job reviewing this TR. It's worth looking at her markup to see the lens that she uses in reviewing a TR. ----Original Message---From: Jones, Samantha Sent: Sunday, May 17, 2015 11:42 PM To: D'Amico, Louis; Rieth, Susan Subject: Fwd: Next set of RDX comments... > Hi, > So, I was able to read through the remainder of the noncancer dose-response (pages 2-8 to 2-17) and some of the cancer hazard and dose-response (but not much). I didn't get as far as I had hoped but I am going to call it quits for now. I will definitely read the cancer when i'm back as apparently I've saved the best for last. Although, considering how the assessment has been so far, I doubt I have any major comments. > Let me know if you have any questions. I'll be checking my work email but infrequently. If you need me, text my cell a Personal Matters / Ex. 6 > See you next Friday! Or perhaps see you next Tuesday since both of you are likely compressed when I'm back 🛈 > Thanks > Samantha